News | Cardiac Imaging | October 18, 2022

HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap Analysis

HeartFlow is the first and only company to provide non-invasive anatomy, physiology, and plaque information based on coronary computed tomography angiography (CCTA) 

HeartFlow is the first and only company to provide non-invasive anatomy, physiology, and plaque information based on coronary computed tomography angiography (CCTA)

October 18, 2022 —  HeartFlow, Inc., a leader in revolutionizing precision heart care, has received U.S. Food and Drug Administration (FDA) 510(k) clearance on two new, AI-powered products: Plaque analysis and RoadMap analysis. With its expanded product portfolio, HeartFlow is the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology (HeartFlow FFRCT), and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain a more comprehensive understanding of a patient’s coronary artery disease (CAD) and are the most accurate approach to predict risk of a heart attack.1 

“The 510(k) clearance of our Plaque and RoadMap analyses represents a major milestone in the company’s commitment to provide physicians with richer clinical insights to help diagnose and treat individual patients, no matter where they are on the coronary disease spectrum,” said John Farquhar, President and Chief Executive Officer, HeartFlow. “FFRCT has already been recognized by the recent ACC/AHA Chest Pain Guidelines and is poised to change the standard-of-care in patients. Plaque and RoadMap analyses, together with FFRCT, establish HeartFlow’s platform technologies and will enable further development of AI-powered risk scoring to better identify asymptomatic patients at risk of heart attack.” 

HeartFlow’s Plaque analysis has been studied in 11,000+ patients and will provide physicians with comprehensive and actionable data showing plaque characteristics and volume in all major coronary arteries.2 It enables critical information regarding coronary plaque to be delivered conveniently to physicians along with anatomy and physiology.3 Centers for Medicare & Medicaid Services recently announced that, as of October 1, 2022, the plaque analysis is paid as a separate service in the hospital outpatient department. 

The RoadMap analysis will enable CT readers to improve CAD diagnosis by providing visualization and quantification of the location and severity of anatomic narrowings in the coronary arteries on every CCTA. It has been shown to provide reproducible results and can help enable efficient, standardized, and high quality CT interpretation.4 

“It is exciting to note the work HeartFlow is doing to bring forward the innovative technologies to help us advance our understanding and care for patients with coronary artery disease. Combining anatomy, physiology, and plaque morphology would be essential for personalized patient care,” said Jagat Narula, MD, PhD, Chief of Cardiology at Mount Sinai Morningside Hospital

With this FDA 510(k) clearance, HeartFlow will begin real-world clinical use of the Plaque and RoadMap analyses with select hospitals and health systems. HeartFlow’s latest technologies will play a vital role in improving cardiovascular patient care. 

For more information: www.heartflow.com 

Related Chest Pain Imaging Content: 

First International Chest Pain Diagnosis Guidelines Released 

VIDEO: Why the ASNC Did Not Endorse the 2021 Chest Pain Guidelines — Interview with ASNC President Dennis Calnon, M.D. 


Related Content

News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

Home March 01, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
Subscribe Now